§ Claim under review · Mixed
"Researchers have developed a smart molecule capable of dramatically boosting memory in just 48 hours... The drug, known as ISRIB, was tested on mice, and the results were astonishing: animals suffering from learning impairments or brain injuries regained the ability to remember up to 70% more routes, locations, and complex tasks only two days after treatment." Sourced to: "ScienceDaily – Drug shows rapid improvement in memory and cognition" (https://www.sciencedaily.com/releases/2025/02/250204141840.htm). Accompanied by: "which supplements are actually worth taking to improve memory? I've linked them all in my bio."
Verdict
False
Confidence
HighSummary
The drug in this post is real and so is the research behind it, but the post's key details are not. ISRIB was discovered at UC San Francisco in 2013, and studies in mice published in 2013, 2017 and 2020 did show fast memory improvement in healthy mice, brain injured mice and aged mice after only a few doses. However, the "70 percent" improvement figure does not appear in any of that published research, which measures things like how quickly a mouse finds a hidden platform in a maze, not a percentage of memories. The ScienceDaily link in the post does not discuss ISRIB at all. It is about a different experimental drug called GL II 73 from a different institution. All of the memory evidence comes from mice, there is no human evidence that ISRIB improves memory, one published study found it failed to improve memory in an Alzheimer's mouse model, and drugs targeting the same pathway failed their main goals in human ALS trials in 2025. The scientist who discovered ISRIB has publicly warned against people buying and taking it, and it is not a supplement, so the research offers no support for whatever products are linked in the post's bio.
The readings
key figures from the evidenceclaimed memory improvement in mice after ISRIB treatment
time frame claimed for memory boost after treatment
time after TBI when ISRIB rescued behavioral deficits in mice
Why this verdict
Evidence
The cited source does not describe ISRIB. The URL in the post resolves to a February 4, 2025 ScienceDaily release from the Centre for Addiction and Mental Health about a completely different compound: a study showing an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease . The headline the post attributes to ScienceDaily ("Drug shows rapid improvement in memory and cognition") does not match that page, which is titled "New drug shows promise in reversing memory loss for early Alzheimer's patients."
ISRIB itself is real and the memory research is real, but it is older than implied. Scientists demonstrated that a novel, drug-like molecule called ISRIB (integrated stress response inhibitor) can improve cognitive memory in mice, with ISRIB-treated mice displaying significant enhancement in spatial and fear-associated learning. That work dates to June 2013, not 2025. ISRIB first appeared in medical literature in 2013 when it was studied in a mouse model of memory enhancement.
The brain injury finding is real. In the 2017 UCSF work, both normal and brain-injured mice were placed in a "radial-arm water maze," in which they had to learn the location of a platform hidden under milky water in one of eight arms of the maze , and the drug fully restored the ability to learn and remember in the brain-injured mice even when the animals were treated weeks after injury . The PNAS paper reports that ISRIB treatment rescues TBI-induced behavioral deficits on the radial arm water maze 28 days after focal TBI .
The aging finding is real and is the origin of the "within days" framing. Just a few doses of the experimental drug can reverse age-related declines in memory and mental flexibility in mice, according to UC San Francisco scientists, and the drug had already been shown to restore memory function months after traumatic brain injury, reverse cognitive impairments in Down Syndrome, prevent noise-related hearing loss, fight certain types of prostate cancer, and even enhance cognition in healthy animals. Specifically, aged animals who received small daily doses of ISRIB during the three-day training process were able to accomplish the task as well as youthful mice, much better than animals of the same age who didn't receive the drug .
No "70%" figure appears in any of the retrieved primary or institutional sources. The published outcome measures are latency to find a platform, arm entry errors, and freezing time in fear conditioning, not a percentage of "routes, locations, and complex tasks remembered."
There is also a published negative result that the post omits while invoking Alzheimer's. In an Alzheimer's mouse model, researchers did not observe a significant rescue effect with ISRIB treatment on spatial learning and memory as assessed in the Morris water maze in J20 mice, and also did not observe a significant enhancement of spatial learning or memory in nontransgenic mice, although a trend emerged for memory enhancement in one cohort .
In humans, drugs acting on the same target have not succeeded. DNL343 and fosigotifator are designed to act on the integrated stress response pathway protein eIF2B, and both failed to slow ALS progression in the HEALEY trial.
Denali's DNL343 failed to meet its primary endpoint of overall function and survival, and fosigotifator targets eIF2B, essential for protein synthesis and a key regulator of the integrated stress response. These were ALS trials, not memory trials, but they are the only late-stage human data on this mechanism.
Researchers have explicitly cautioned against self-experimentation. Experts warn that interfering with vital cellular mechanisms, as ISRIB seems to do, could lead to a host of dangerous side effects, and caution that it will be years, or possibly decades, before it is ready for testing in humans.
Word of the compound reached communities of "brain hackers," and to Walter's dismay, some are buying ISRIB online and ingesting it.
Findings
✓ What's accurate 5
- ISRIB exists and was developed at UCSF in Peter Walter's laboratory.
- It improved memory performance in mice, including healthy mice, brain-injured mice, and aged mice.
- Behavioral improvements appeared rapidly, within days and after only a few doses, which is unusual for neurological interventions.
- The mechanism described in the post is broadly correct: ISRIB inhibits the integrated stress response, a translation-arresting pathway involving eIF2 and eIF2B.
- Researchers have publicly speculated about eventual relevance to brain injury and age-related cognitive decline.
≈ What's misleading 9
- False source attribution: the linked ScienceDaily URL is about GL-II-73, a different drug from a different institution. This is a fabricated citation attached to a real page.
- Fabricated statistic: the "up to 70% more routes, locations, and complex tasks" figure does not appear in any retrieved primary source or institutional press release. The published studies do not report memory in that unit.
- Species extrapolation: results in mice are presented as a general statement about "memory" and "the brain," with no qualification that no human memory evidence exists.
- Temporal overreach and date mismatch: the core findings are from 2013, 2017 and 2020, presented as a current 2025 breakthrough.
- Journal misattribution: "published in Science" is incorrect for the memory findings.
- Omitted qualifier: the post does not mention the published failure of ISRIB to rescue memory in an Alzheimer's mouse model, while promoting Alzheimer's relevance and using #Alzheimers.
- Omitted qualifier: human trials of drugs hitting the same target have failed their primary endpoints.
- Marketing as evidence: the post pivots from ISRIB research to "supplements linked in my bio." ISRIB is not a supplement and no supplement in any bio link has been shown to produce the effects described. The research provides no support whatsoever for the products being sold.
- Exaggeration: "as if the brain had become younger" and "70% younger" restate a mouse behavioral task result as biological age reversal.
? What's uncertain 4
- Whether the "70%" figure was invented outright or mis-derived from a specific figure panel in one of the papers. I could not locate it in any source, but I cannot prove no such number exists in any supplementary table.
- The exact origin of the headline "Drug shows rapid improvement in memory and cognition." The closest real ScienceDaily headline is "Drug reverses age-related mental decline within days, mouse study shows" (December 2020).
- Which specific supplements the post links, and therefore whether any separate claims about them hold up. This was not investigable from the material provided.
- Long-term safety of ISR inhibition in humans, which remains unestablished.
Sources
7 of 8 linked to recordsScienceDaily release 250204141840 (the exact URL cited in the post)—secondary (press release aggregation)
Krukowski et al., eLife, 1 Dec 2020, "Small molecule cognitive enhancer reverses age-related memory decline in mice"
Chou et al., PNAS, 10 July 2017, "Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury"
Sidrauski et al. (2013), ISRIB discovery, Walter lab UCSF
Johnson/Gan-era negative study, hAPP-J20 Alzheimer's mouse model
Denali Therapeutics and Calico/AbbVie HEALEY ALS Platform Trial topline results, Jan 2025
STAT News profile of Peter Walter (2016)
ALSUntangled #80 review of ISRIB, 2025